Medical device and regenerative medicine company TBYR Health has earned FDA clearance for its B3 gel system, a bioresorbable gel barrier that protects healing tissue planes and preserves mobility following tendon, ligament and skeletal muscle surgeries.
The gel, which is composed of a naturally derived extracellular matrix, helps to temporarily separate tissues during the bone healing phase, according to a June 9 news release.
It can be used for patients following both open and minimally invasive procedures. Commercial sales of the gel will begin by the end of 2025.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
